ImmunoCellular Therapeutics, Ltd. (IMUC)
USD 0.15
(53.85%)
USD 0.15
(53.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.61 Million USD | 39.07% |
| 2022 | -2.64 Million USD | 1.2% |
| 2021 | -2.67 Million USD | -84.39% |
| 2020 | -1.45 Million USD | 0.0% |
| 2017 | -18.51 Million USD | 20.86% |
| 2016 | -23.39 Million USD | -81.03% |
| 2015 | -12.92 Million USD | -37.61% |
| 2014 | -9.39 Million USD | -7.34% |
| 2013 | -8.75 Million USD | 39.63% |
| 2012 | -14.49 Million USD | -153.42% |
| 2011 | -5.71 Million USD | 7.0% |
| 2010 | -6.15 Million USD | -134.18% |
| 2009 | -2.62 Million USD | 14.17% |
| 2008 | -3.05 Million USD | 15.35% |
| 2007 | -3.61 Million USD | 29.85% |
| 2006 | -5.15 Million USD | -1994.56% |
| 2005 | -246 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -1.61 Million USD | 39.07% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q4 | -464.52 Thousand USD | 39.12% |
| 2022 Q3 | -762.99 Thousand USD | -20.33% |
| 2022 Q1 | -785.3 Thousand USD | -26563.28% |
| 2022 Q2 | -634.08 Thousand USD | 19.26% |
| 2022 FY | -2.64 Million USD | 1.2% |
| 2021 Q3 | -501.92 USD | 0.0% |
| 2021 Q1 | -1 Million USD | -73963.28% |
| 2021 FY | -2.67 Million USD | -84.39% |
| 2021 Q4 | -2945.28 USD | -486.8% |
| 2020 Q3 | -412.27 USD | 0.0% |
| 2020 Q4 | -1359.55 USD | -229.77% |
| 2020 FY | -1.45 Million USD | 0.0% |
| 2018 Q1 | -1.02 Million USD | -137.65% |
| 2018 Q2 | -306.31 Thousand USD | 70.11% |
| 2017 FY | -18.51 Million USD | 20.86% |
| 2017 Q3 | -3.9 Million USD | 3.42% |
| 2017 Q2 | -4.03 Million USD | 30.66% |
| 2017 Q1 | -5.82 Million USD | 7.9% |
| 2017 Q4 | -431.29 Thousand USD | 88.94% |
| 2016 Q1 | -5.63 Million USD | -17.12% |
| 2016 Q4 | -6.32 Million USD | -31.83% |
| 2016 FY | -23.39 Million USD | -81.03% |
| 2016 Q3 | -4.79 Million USD | 9.98% |
| 2016 Q2 | -5.32 Million USD | 5.39% |
| 2015 FY | -12.92 Million USD | -37.61% |
| 2015 Q1 | -1.42 Million USD | 33.02% |
| 2015 Q3 | -3.4 Million USD | -7.81% |
| 2015 Q4 | -4.8 Million USD | -41.42% |
| 2015 Q2 | -3.15 Million USD | -121.41% |
| 2014 Q1 | -3.16 Million USD | -2802.59% |
| 2014 Q3 | -1.88 Million USD | 14.09% |
| 2014 FY | -9.39 Million USD | -7.34% |
| 2014 Q2 | -2.19 Million USD | 30.45% |
| 2014 Q4 | -2.12 Million USD | -12.59% |
| 2013 Q1 | -4.97 Million USD | -1128.2% |
| 2013 FY | -8.75 Million USD | 39.63% |
| 2013 Q4 | 116.99 Thousand USD | 103.08% |
| 2013 Q3 | -3.79 Million USD | -2423.43% |
| 2013 Q2 | -150.32 Thousand USD | 96.98% |
| 2012 Q3 | -637.62 Thousand USD | 90.12% |
| 2012 Q2 | -6.45 Million USD | 18.22% |
| 2012 FY | -14.49 Million USD | -153.42% |
| 2012 Q1 | -7.88 Million USD | -426.41% |
| 2012 Q4 | 483.74 Thousand USD | 175.87% |
| 2011 Q4 | -1.49 Million USD | -1804.79% |
| 2011 FY | -5.71 Million USD | 7.0% |
| 2011 Q1 | -2.75 Million USD | -9.47% |
| 2011 Q2 | -1.55 Million USD | 43.78% |
| 2011 Q3 | 87.91 Thousand USD | 105.67% |
| 2010 Q1 | -768.46 Thousand USD | 9.97% |
| 2010 Q4 | -2.51 Million USD | -110.78% |
| 2010 Q3 | -1.19 Million USD | 28.27% |
| 2010 FY | -6.15 Million USD | -134.18% |
| 2010 Q2 | -1.66 Million USD | -116.86% |
| 2009 Q4 | -853.59 Thousand USD | -126.46% |
| 2009 Q1 | -599.58 Thousand USD | 13.91% |
| 2009 Q2 | -796.1 Thousand USD | -32.78% |
| 2009 Q3 | -376.92 Thousand USD | 52.65% |
| 2009 FY | -2.62 Million USD | 14.17% |
| 2008 Q1 | -1.14 Million USD | -253.55% |
| 2008 FY | -3.05 Million USD | 15.35% |
| 2008 Q4 | -696.47 Thousand USD | -23.46% |
| 2008 Q3 | -564.15 Thousand USD | 13.12% |
| 2008 Q2 | -649.36 Thousand USD | 43.52% |
| 2007 FY | -3.61 Million USD | 29.85% |
| 2007 Q4 | -325.2 Thousand USD | -46.31% |
| 2007 Q3 | -222.27 Thousand USD | -209.2% |
| 2007 Q2 | 203.54 Thousand USD | 106.22% |
| 2007 Q1 | -3.27 Million USD | 32.33% |
| 2006 FY | -5.15 Million USD | -1994.56% |
| 2006 Q1 | -175.27 Thousand USD | 0.0% |
| 2006 Q2 | -67.14 Thousand USD | 61.69% |
| 2006 Q3 | -76.61 Thousand USD | -14.11% |
| 2006 Q4 | -4.83 Million USD | -6208.72% |
| 2005 FY | -246 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -20.765% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 76.904% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.044% |
| Nascent Biotech, Inc. | -2.08 Million USD | 22.75% |
| Rebus Holdings, Inc. | -1.02 Million USD | -58.111% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.476% |
| Qrons Inc. | -789.34 Thousand USD | -104.313% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -155.016% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.424% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -288.163% |
| Skye Bioscience, Inc. | -37.64 Million USD | 95.716% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.849% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 75.476% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -489.878% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.97% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 44.242% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 11.414% |
| Mesoblast Limited | -87.95 Million USD | 98.166% |
| Marizyme, Inc. | -65.34 Million USD | 97.532% |
| Genus plc | 7.9 Million USD | 120.414% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 85.193% |
| Pharming Group N.V. | -10.54 Million USD | 84.71% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 25.674% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 56.533% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 81.765% |
| ContraFect Corporation | -65.15 Million USD | 97.525% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 66.993% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 6.641% |
| IMV Inc. | -36.48 Million USD | 95.58% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 79.99% |
| MultiCell Technologies, Inc. | -380.07 USD | -424226.308% |
| ONE Bio Corp. | 8.67 Million USD | 118.587% |
| Accustem Sciences Inc. | -3.74 Million USD | 56.953% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 96.88% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -27.274% |
| Q BioMed Inc. | -2.05 Million USD | 21.41% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 56.798% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 32.263% |
| Biomind Labs Inc. | -1.21 Million USD | -32.81% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.3% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 48.006% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 79.594% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 17.264% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -10668.81% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 89.839% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 72.277% |
| GB Sciences, Inc. | -1.36 Million USD | -18.438% |
| Alpha Cognition Inc. | -13.77 Million USD | 88.29% |
| HST Global, Inc. | -146.21 Thousand USD | -1003.028% |
| CSL Limited | 2.64 Billion USD | 100.061% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 8.094% |
| Halberd Corporation | -79.67 Thousand USD | -1924.119% |
| Enzolytics Inc. | -2.17 Million USD | 25.914% |
| Agentix Corp. | -1.37 Million USD | -17.357% |
| Resverlogix Corp. | -3.61 Million USD | 55.326% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 49.148% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.453% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1745.65% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 123.29% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 59.408% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 46.706% |
| AVAX Technologies, Inc. | -6.41 Million USD | 74.855% |
| Zenith Capital Corp. | -10.59 Million USD | 84.78% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.311% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -6838.891% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 61.101% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2568.3% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 19.569% |
| Kadimastem Ltd | -3.3 Million USD | 51.238% |
| Helix BioMedix, Inc. | -1.05 Million USD | -52.713% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 57.771% |
| BioStem Technologies, Inc. | -8.48 Million USD | 80.989% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -265.394% |
| LadRx Corporation | 400.44 Thousand USD | 502.738% |
| Cell Source, Inc. | -5.32 Million USD | 69.692% |
| Regen BioPharma, Inc. | 1.02 Million USD | 257.57% |
| Regen BioPharma, Inc. | 1.02 Million USD | 257.57% |
| NovAccess Global Inc. | -4.76 Million USD | 66.184% |
| Affymax, Inc. | -14.42 Million USD | 88.819% |
| Itoco Inc. | -1.86 Million USD | 13.711% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 63.698% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 3.371% |
| Mobile Lads Corp. | -2.26 Million USD | 28.744% |
| CytoDyn Inc. | -49.84 Million USD | 96.764% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1940.587% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -606.947% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -71.289% |
| SYBLEU INC | -180.3 Thousand USD | -794.454% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| International Stem Cell Corporation | -131 Thousand USD | -1131.097% |
| Bioxytran, Inc. | -4.28 Million USD | 62.319% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2871.582% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 36.262% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 96.645% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 23.712% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -106.526% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 49.093% |
| Neutra Corp. | -233.46 Thousand USD | -590.783% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 92.052% |
| PureTech Health plc | -65.69 Million USD | 97.545% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 92.417% |
| IXICO plc | -1.17 Million USD | -36.905% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 83.754% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.177% |
| CSL Limited | 2.64 Billion USD | 100.061% |
| Cellectis S.A. | -103.17 Million USD | 98.437% |